2013 BIO Convention in China Preliminary Program Topics

  • Recommend
  • Tweet
  • Print
  • Email

Topics subject to change. To view the 2012 BIO Convention in China Program, please click here.

For questions about programming, or to contact BIO regarding program participation, please contact Celia Economides, Director of Investor Relations & Programming at ceconomides@bio.org.

Policy Focused Sessions

  • China Private Health Care Industry

    • Public desire for more modern healthcare options and changes in regulations are creating an environment conducive to a growing private healthcare industry in China. The growth of this industry will have major implications for the reimbursement of biopharmaceutical products Chinese patients’ ability to access the best and most innovative medicines.

  • Building a World-Class Innovative Therapeutic Biologics Industry in China

    • BIO and R&D Based Pharmaceutical Association Committee (RDPAC) have commissioned a multi-year study on best practices in building an innovative therapeutic biologics industry in China, exploring success and failures in other markets. Key recommendations are made with the intention of providing a foundation for revision on the next five-year plan as it relates to biotechnology, one of China’s seven Strategic Emerging Industries (SEIs).

  • China’s New Party Leadership, Implications for Central Planning and Regulation

    • This past March, China went through a historic leadership transition. As the new president, Xi Jinping, takes the helm and ministries like the China Food & Drug Administration (CFDA) are elevated in importance, what are the implications for the biotechnology industry in China?

  • Looking Forward: 13th Five-year Plan & Its Investment in Innovation

    • As China’s 12th Five-year Plan concludes in 2015, the country begins to lay the groundwork for the 13th Five-year Plan for 2016-2020. This panel will explore lessons learned, areas of strength, areas for improvement, and where industry can support central planners moving forward.

Scientific Focused Sessions

  • Cancer Epigenetics and Emerging Therapies

    • Ten years after the sequencing of the human genome, the use of epigenetics in developing targeted cancer treatments is rapidly growing. What are recent discoveries in epigenetic abnormalities and what are the implications for cancer treatment? What emerging therapies are on the forefront of this new and cutting-edge research?

  • Treating NSCLC in China 

    • Lung cancer is the leading cause of death in the world and prevalence of NSCLC in China is no exception. Prominent oncologists from both the clinic and the bench will provide their insights on this growing treatment market. How do branded Western drugs fare against the Chinese competitors? Which drugs currently dominate the Chinese NSCLC market and how will the market continue to grow?

  • Traditional Chinese Medicine

    • China has used Traditional Chinese Medicine (TCM) for centuries and still comprises a substantial portion of the Chinese healthcare industry. How are these medicines used in China and what are the opportunities for TCM outside of China?

  • Diabetes Dx and Treatment in China

    • As the prevalence of diabetes continues to rise in China, the country plans to enact regulations to screen high-risk populations, necessitating the availability of more treatments across the country. Several pharmacos have already increased their distribution and manufacturing capabilities of these new medications. What’s in the diagnostics pipeline for identifying these at-risk populations? What is currently the standard of care and how will that change in the next few years?

  • Respiratory Disease in China—Treatment and Prevention

    • According to the World Health Organization (WHO), chronic respiratory disease is the 2nd leading cause of death in China. Chronic obstructive pulmonary disease (COPD) is rapidly increasing as a public health concern in the country, necessitating proper education, diagnosis and treatment. This panel will explore current treatment paradigms, both in TCM and western medicine, in addition to current research and prevention mechanisms.

  • Vaccines 

    • Hand, foot, and mouth disease continues to represent a significant unmet public health need and economic burden in China, as well as several other Asian countries. Flu also continues to be rampant in China. What vaccines are being used and what vaccines are in late stage development that can be leveraged in the at-risk populations in China?

  • Rare Diseases in China  

    • The establishment of China’s first national organization against rare diseases (China Rare Diseases Prevention & Treatment Alliance) reaffirms the country’s commitment to innovative health care research. China is actively promoting the regulation of rare diseases and orphan drugs. This panel will focus on the research and development of orphan drugs in China.

Business Focused Sessions

  • New VC Models in China

    • Innovative drug development programs in China are growing rapidly, which--combined with the ongoing reform of CFDA towards better performance and faster time to market--theoretically shall turn the country into a new El Dorado for biotech venture capitalists and private equity investors. Reality is, however, quite far away from this idyllic picture: among other factors, under-performing local stock markets and relatively scarce trade sale opportunities result in many VC/PE facing only limited exit options. Shall investors simply adjust their expectations while waiting for the environment to mature, or are there China-specific investment/exit models to explore?

  • State of Capital Markets in China

    • For the unprepared investor, capital markets in China can easily challenge usual habits and expectations. Unique market sensitivity factors, among which non-convertible currency, collide to hinder market efficiency, especially in the biopharma sector where success stories are rarer than offers to go private (Simcere Pharmaceuticals undoubtedly being the most prominent recent example). This panel will explore the realm of the state of the capital markets in China through the prism of the biotech industry, assess the current and future attractiveness of local IPOs, and carry the debate towards a global perspective to provide both biotechs and investors with applicable insights.

  • Digital & E-Health in China

    • Healthcare IT has become an integral force in managing health globally, and China is no exception. The Chinese government intends to further develop digital and e-health to provide better quality delivery of services and education. This panel will explore how China’s healthcare IT system compares and contrasts to that of the West and how this rapidly growing field continues to evolve in China and beyond.

  • Medical Insurance in China 

    • The China Insurance Regulatory Commission (CIRC) recently set requirements for major disease insurers. This panel will explore the recent guidelines, requirements, and implementation strategies.

  • Opportunities from EDL expansion  

    • Recently, China’s Ministry of Health released the widely anticipated expansion of the essential drug to list (EDL) to 520 drugs (from 307) to cover diseases such as cancers. With the market share of EDLS drugs continue to grow, opportunities exist for both western pharma and Chinese TCM companies. This panel will explore the expanded EDL list how companies can best leverage this opportunity.